Provectus Biopharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 4
- Market Cap
- -
- Website
- http://www.provectusbio.com
A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver
- Conditions
- Interventions
- First Posted Date
- 2016-02-26
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Provectus Biopharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02693067
- Locations
- 🇦🇺
The Queen Elizabeth Hospital, Woodville, South Australia, Australia
PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma
- First Posted Date
- 2015-09-23
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Provectus Biopharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT02557321
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
- Conditions
- Interventions
- First Posted Date
- 2014-11-11
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Provectus Biopharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02288897
- Locations
- 🇺🇸
Sharp Memorial Hospital - Clinical Oncology Research, San Diego, California, United States
🇺🇸M.D. Anderson Cancer Center, Houston, Texas, United States
🇲🇽Neurociencias Estudios ClÃnicos S.C., Culiacán, Sinaloa, Mexico
Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors
- First Posted Date
- 2010-12-15
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- Provectus Biopharmaceuticals, Inc.
- Registration Number
- NCT01260779
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇦🇺Royal Adelaide Hospital Cancer Centre, Adelaide, South Australia, Australia
🇺🇸St Luke's University Health Network, Bethlehem, Pennsylvania, United States
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
- Conditions
- Interventions
- First Posted Date
- 2009-09-30
- Last Posted Date
- 2022-11-02
- Lead Sponsor
- Provectus Biopharmaceuticals, Inc.
- Target Recruit Count
- 78
- Registration Number
- NCT00986661
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Florida Hospital Tampa, Tampa, Florida, United States
🇺🇸Sharp Memorial Hospital, San Diego, California, United States